Market Cap 38.03B
Revenue (ttm) 3.71B
Net Income (ttm) 313.75M
EPS (ttm) N/A
PE Ratio 80.84
Forward PE 40.09
Profit Margin 8.45%
Debt to Equity Ratio 0.00
Volume 975,800
Avg Vol 1,133,220
Day's Range N/A - N/A
Shares Out 133.51M
Stochastic %K 23%
Beta 0.31
Analysts Strong Sell
Price Target $450.48

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products i...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 551 8200
Fax: 617 551 8101
Address:
675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States
NVDAMillionaire
NVDAMillionaire May. 13 at 9:21 PM
$ALNY Brilliant piece that captures ALNY's situation perfectly. So if you want to update your understanding of ALNY or get to know ALNY better, this is essential reading. https://everyticker.com/quote/ALNY/analysis/rnai-platform-validation-meets-cardiomyopathy-inflection-alnylam-s-path-to-multi-product-dominance-nasdaq-alny
0 · Reply
MarketBeat
MarketBeat May. 13 at 8:14 PM
https://marketbeat.com/a/8652921/ $ALNY Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build
0 · Reply
OffHisGame88
OffHisGame88 May. 12 at 3:29 PM
$ALNY adding
0 · Reply
akinyo
akinyo May. 11 at 5:07 PM
$ALNY damn! What’s going on with ALNY?! 😳
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 2:49 PM
$ALNY Current Stock Price: $292.51 Contracts to trade: $290.0 ALNY May 15 2026 Call Entry: $6.10 Exit: $9.60 ROI: 57% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Kool_Aid_Mann
Kool_Aid_Mann May. 8 at 7:53 PM
$VRTX $ALNY $REGN Join MNKD as they approach their May 29th pediatric PDUFA!! This is the one that they have been waiting for for 12 years. Lots of delays, but finally here and likely to be the milestone trigger for a big cash deal with big pharma! On top of that, they just got back the green light for Treprostinil DPI in IPF which had them previously trading over $6 until a spat with their partner UTHR. Now, not only is everything copacetic again, but they have also just announced a new molecule colloboration with bigger potential than Trep, Ralinpag DPI! Big royalty model like $LGND But wait, there's more, there is another PDUFA ahead for them for furoscix on July 26th, that will approve a new auto injector that will make this product best in class and reduce COGs by 70% to create massive profits. And lets not forget that nintedabib DPI just finished 1b and is prime for an upfront cash deal! $VCYT Fireworks ahead, fight the Citadel!
0 · Reply
Quantumup
Quantumup May. 8 at 10:52 AM
Evercore ISI⬆️the PT on $BBIO to $130 (was $125), reiterated at Outperform, and said: Attruby's strengthening commercial performance once again highlighted BBIO's 1Q print. $PFE $ALNY TYRA SNY Here's what else Evercore ISI had to say: https://x.com/Quantumup1/status/2052702376100819209?s=20
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 8 at 12:56 AM
$ALNY RSI: 39.15, MACD: -6.3792 Vol: 12.59, MA20: 311.12, MA50: 317.10 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
biotech
biotech May. 7 at 9:44 AM
$SGMO May 12 $SGMO is on a RNAi Panel together with John Maraganore ( $ALNY ) also talking about #CMC on another panel ... re #FABRY BLA
0 · Reply
WAJeff
WAJeff May. 4 at 6:32 PM
$ALNY Think $280-295 add level will work or is this too broken?
1 · Reply
Latest News on ALNY
Alnylam price target lowered to $447 from $448 at Bernstein

2026-05-01T14:21:06.000Z - 12 days ago

Alnylam price target lowered to $447 from $448 at Bernstein


Alnylam reports Q1 EPS $1.99, consensus $1.47

2026-04-30T16:59:31.000Z - 13 days ago

Alnylam reports Q1 EPS $1.99, consensus $1.47


Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 13 days ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026


Alnylam price target lowered to $505 from $515 at Truist

2026-04-13T13:43:03.000Z - 4 weeks ago

Alnylam price target lowered to $505 from $515 at Truist


Alnylam presents new data on vutrisiran in ATTR-CM at ACC.26

2026-03-30T17:11:15.000Z - 6 weeks ago

Alnylam presents new data on vutrisiran in ATTR-CM at ACC.26


Alnylam Pharmaceuticals Transcript: Status update

Mar 24, 2026, 9:30 AM EDT - 7 weeks ago

Alnylam Pharmaceuticals Transcript: Status update


Alnylam downgraded to Hold from Buy at Jefferies

2026-03-16T09:25:22.000Z - 2 months ago

Alnylam downgraded to Hold from Buy at Jefferies


How Alnylam Stock Weathers Market Shocks

Mar 11, 2026, 11:55 AM EDT - 2 months ago

How Alnylam Stock Weathers Market Shocks


Alnylam to Webcast TTR Investor Webinar

Mar 10, 2026, 8:00 AM EDT - 2 months ago

Alnylam to Webcast TTR Investor Webinar


Alnylam price target raised to $429 from $415 at Canaccord

2026-02-17T12:20:41.000Z - 3 months ago

Alnylam price target raised to $429 from $415 at Canaccord


Alnylam price target raised to $429 from $415 at Canaccord

2026-02-17T12:05:53.000Z - 3 months ago

Alnylam price target raised to $429 from $415 at Canaccord


Alnylam price target lowered to $249 from $415 at Canaccord

2026-02-17T12:00:57.000Z - 3 months ago

Alnylam price target lowered to $249 from $415 at Canaccord


Alnylam upgraded to Buy from Hold at Freedom Capital

2026-02-16T22:25:08.000Z - 3 months ago

Alnylam upgraded to Buy from Hold at Freedom Capital


Alnylam Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 12, 2026, 8:30 AM EST - 3 months ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q4 2025


Alnylam Pharmaceuticals Announces Changes to Board of Directors

Dec 3, 2025, 8:00 AM EST - 5 months ago

Alnylam Pharmaceuticals Announces Changes to Board of Directors


UK's drug-cost watchdog recommends Alnylam's heart disease drug

Nov 20, 2025, 7:09 PM EST - 6 months ago

UK's drug-cost watchdog recommends Alnylam's heart disease drug


Alnylam Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 30, 2025, 8:30 AM EDT - 6 months ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q3 2025


Alnylam Pharmaceuticals Transcript: Status Update

Aug 30, 2025, 1:00 PM EDT - 9 months ago

Alnylam Pharmaceuticals Transcript: Status Update


Scenic Enters License and Research Agreement with Alnylam

Aug 26, 2025, 5:00 AM EDT - 9 months ago

Scenic Enters License and Research Agreement with Alnylam


Alnylam Pharmaceuticals Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:30 AM EDT - 10 months ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q2 2025


Alnylam Pharmaceuticals Names Garg R&D Chief

Jun 18, 2025, 12:04 PM EDT - 11 months ago

Alnylam Pharmaceuticals Names Garg R&D Chief


NVDAMillionaire
NVDAMillionaire May. 13 at 9:21 PM
$ALNY Brilliant piece that captures ALNY's situation perfectly. So if you want to update your understanding of ALNY or get to know ALNY better, this is essential reading. https://everyticker.com/quote/ALNY/analysis/rnai-platform-validation-meets-cardiomyopathy-inflection-alnylam-s-path-to-multi-product-dominance-nasdaq-alny
0 · Reply
MarketBeat
MarketBeat May. 13 at 8:14 PM
https://marketbeat.com/a/8652921/ $ALNY Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build
0 · Reply
OffHisGame88
OffHisGame88 May. 12 at 3:29 PM
$ALNY adding
0 · Reply
akinyo
akinyo May. 11 at 5:07 PM
$ALNY damn! What’s going on with ALNY?! 😳
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 2:49 PM
$ALNY Current Stock Price: $292.51 Contracts to trade: $290.0 ALNY May 15 2026 Call Entry: $6.10 Exit: $9.60 ROI: 57% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Kool_Aid_Mann
Kool_Aid_Mann May. 8 at 7:53 PM
$VRTX $ALNY $REGN Join MNKD as they approach their May 29th pediatric PDUFA!! This is the one that they have been waiting for for 12 years. Lots of delays, but finally here and likely to be the milestone trigger for a big cash deal with big pharma! On top of that, they just got back the green light for Treprostinil DPI in IPF which had them previously trading over $6 until a spat with their partner UTHR. Now, not only is everything copacetic again, but they have also just announced a new molecule colloboration with bigger potential than Trep, Ralinpag DPI! Big royalty model like $LGND But wait, there's more, there is another PDUFA ahead for them for furoscix on July 26th, that will approve a new auto injector that will make this product best in class and reduce COGs by 70% to create massive profits. And lets not forget that nintedabib DPI just finished 1b and is prime for an upfront cash deal! $VCYT Fireworks ahead, fight the Citadel!
0 · Reply
Quantumup
Quantumup May. 8 at 10:52 AM
Evercore ISI⬆️the PT on $BBIO to $130 (was $125), reiterated at Outperform, and said: Attruby's strengthening commercial performance once again highlighted BBIO's 1Q print. $PFE $ALNY TYRA SNY Here's what else Evercore ISI had to say: https://x.com/Quantumup1/status/2052702376100819209?s=20
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 8 at 12:56 AM
$ALNY RSI: 39.15, MACD: -6.3792 Vol: 12.59, MA20: 311.12, MA50: 317.10 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
biotech
biotech May. 7 at 9:44 AM
$SGMO May 12 $SGMO is on a RNAi Panel together with John Maraganore ( $ALNY ) also talking about #CMC on another panel ... re #FABRY BLA
0 · Reply
WAJeff
WAJeff May. 4 at 6:32 PM
$ALNY Think $280-295 add level will work or is this too broken?
1 · Reply
SuperGreenToday
SuperGreenToday May. 4 at 4:11 PM
$ALNY Share Price: $295.52 Contract Selected: Sep 18, 2026 $300 Calls Buy Zone: $25.16 – $31.08 Target Zone: $45.34 – $55.42 Potential Upside: 70% ROI Time to Expiration: 136 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
CapitalMonk
CapitalMonk May. 4 at 3:42 PM
$ALNY Price: $294.74 (-0.46%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.14% RSI: 22.3 | Momentum: Strong Downside Volume: -56.9% vs avg Volatility: 2.29% Support: $287.00 | Resistance: $343.36 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
Fingerlickengood
Fingerlickengood May. 4 at 3:19 PM
$CDXS $ALNY https://www.businesswire.com/news/home/20260504658209/en/Alnylam-to-Present-New-Analyses-at-Heart-Failure-2026-Underscoring-Consistent-Clinical-Profile-of-Vutrisiran-in-ATTR-CM
0 · Reply
Fingerlickengood
Fingerlickengood May. 4 at 3:18 PM
$CDXS $ALNY https://www.codexis.com/blogs/accelerating-scalable-and-sustainable-sirna-manufacturing-with-ligation-based-synthesis/
0 · Reply
Fingerlickengood
Fingerlickengood May. 4 at 3:06 PM
$CDXS $ALNY I wouldn't be surprised it Codexis isn't working with Alnylam on enzymatic ligation maufacturing for all thier siRNA drugs currently in multiple stages of clinical trials and development! From their q1 Financial Report they have $3B in cash to boot, easily could acquire Codexis' IP. siRNA drugs they currently have in various stages of clical development: AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran) https://investors.alnylam.com/press-release?id=29796
0 · Reply
akinyo
akinyo May. 1 at 5:43 PM
$ALNY can’t catch a break 😢
0 · Reply
kareem1988
kareem1988 May. 1 at 8:27 AM
Biotech finally catching some meaningful momentum. $DRTS stood out yesterday with a solid 13 percent move, which is great to see given the recent focus on their clinical data. $ALNY is also showing some interesting activity following their earnings report, and $BMY seems to be catching a nice bid after their own solid results. $VRTX is also looking resilient, rounding out a strong day for the space. The sector has been choppy lately, but yesterday felt different. Watching the volume closely today.
1 · Reply
Jblack500
Jblack500 Apr. 30 at 6:36 PM
$ALNY bottomed today. If you blinked you missed it
0 · Reply
Bazzzigar
Bazzzigar Apr. 30 at 4:51 PM
$ALNY as expected
0 · Reply
Jblack500
Jblack500 Apr. 30 at 4:16 PM
@MaverikIT @No_Face_character @cynicaloptimist @IsabellaDC @BustaCapital @WAJeff $ALNY earnings today and reaction off low says this bottomed this morning
0 · Reply
d_risk
d_risk Apr. 30 at 3:36 PM
$ALNY - Alnylam Pharmaceuticals Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +185.7% above peer average (34,131 vs 11,948 across 652 peers). ALNY’s new 10-Q flags fresh risks around reliance on CROs and third-party manufacturing, talent retention, funding needs, Leqvio royalty exposure, FX/tax/treasury risks, collaboration instability, AI and cybersecurity, clinical/regulatory setbacks, pricing and reimbursement pressure (including ex-US price controls), expansive compliance and IP/exclusivity threats, and continued stock volatility. 🟢 Added 🟠 Removed https://d-risk.ai/ALNY/10-Q/2026-04-30
0 · Reply
judgeyoung2
judgeyoung2 Apr. 30 at 1:24 PM
$ALNY they are fumbling the cc
1 · Reply